Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Sponsor: National Cancer Institute (NCI)
Terminated
Inadequate accrual rate
Other terminated trials from National Cancer Institute (NCI)
Listed as NCT03031730, this PHASE1 trial focuses on Plasmacytoma and Recurrent Multiple Myeloma and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 49 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
49 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Feb 2026 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 44 earlier versions
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Jul 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Aug 2018 — Mar 2019 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Mar 2018 — May 2018 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .